At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...
The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...
Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of ...
States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump ...
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback